US pharma associations clash over Trans-Pacific Partnership (TPP)

Published: 3-Jul-2015
Regulatory

After President Obama secures trade promotion authority powers


A difference of opinion has emerged between US pharmaceutical industry associations over the securing of trade promotion authority (TPA) by President Obama to help him finalise new trade deals. The new powers will enable him to propose negotiated deals for 'yes' or 'no' votes in the US Congress without the ratification process being subject to detailed amendments. This is expected to enable the US to secure a deal on the Trans-Pacific Partnership (TPP) agreement with Pacific Rim countries, and speed up talks with the Transatlantic Trade and Investment Partnership (TTIP) with the European Union.

Of these, talks on the TPP are further developed and, according to Mark Grayson, spokesperson for the Pharmaceutical Research and Manufacturers of America (PhRMA), US pharma manufacturers would support this deal provided it includes 'strong intellectual property protections', as expected. He said: 'We do believe it's better' to have tough IP rules, 'not just for us but for encouraging an environment of innovation in all these countries'.

But David Gaugh, Senior Vice President for Sciences and Regulatory Affairs at the Generic Pharmaceutical Association (GPhA) was concerned that the TPP might grant excessive protection.

'While American manufacturers of generic medicines need a TPP that will help them continue to grow their exports and create American jobs, while improving patients’ health, the current language fails to do that,' he said.

'Instead, the intellectual property provisions in TPP are designed to give longer protection to patented drugs and postpone the entry of cost-saving generic drugs and biosimilars, impeding patient access.'

  • Companies:
  • Pharmaceutical Research and Manufacturers of America
  • GPhA Generic Pharmaceutical Association
See more

You may also like

Regulatory

PhRMA board talk with President Trump

Read more
PhRMA CEO has issued a statement following his meeting with President Trump regarding the US biopharmaceutical industry

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
  3. Post-Brexit border paperwork and inspections postponed for life sciences sector The six month extension will allow life science companies to the make necessary alterations to their supply chains to accommodate for the novel post-Brexit border paperwork
  4. PCI Pharma Services PCI Pharma Services: Your bridge between life-changing therapies and patients.
  5. How to proactively address EU HTAR implementation challenges before 2025 Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

PhRMA board talk with President Trump

PhRMA CEO has issued a statement following his meeting with President Trump regarding the US biopharmaceutical industry
Manufacturing

FDA reaches agreement on GDUFA amendments for new five-year term

Will enable the FDA to ensure access to safe and effective generic medicines
Regulatory

Small changes would make a big difference, say European pharma representatives

Pharmaceutical industry seeks savings through simplification rather than a radical regulatory overhaul at transatlantic trade talks
Regulatory

Sanofi to expand access to clinical trial data

In support of PhRMA and EFPIA principles on responsible sharing of data
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now